Table 1. Summary of 15 types of cancer studies included in current meta-analysis.
IHC, immunohistochemistry; WB, western blot; RCR, polymerase chain reaction; FACS, fluorescence-activated cell sorting.
| Disease | No.of studies | Subtype | Location | Detetction method | No.of patients (CXCR4: +/−) | Average size of studies(range) | Average size of CXCR4+ patients(range) | Average age(years) | Average follow-up(months) |
|---|---|---|---|---|---|---|---|---|---|
| Hematological malignancy | 7 | Acute myeloid leukemia,5 (n=456); Myelodysplastic syndrome,1 (n=81); multiple myeloma,1 (n=227) |
North america, 4 (n=366); Europe, 1 (n=90); Asia, 2（n=308） |
IHC, 3 (n=276); FACS, 4 (n=488) |
764(413/351) | 109(53-227) | 59(26-98) | 57 | 13 |
| Breast cancer | 18 | Triple negative breast cancer,3 (n=374); Node-positive breast cancer,2 (n=318); Node-negative breast cancer,2 (n=295); Locally advanced breast cancer, 2 (n=131); Inflammatory breast cancer, 1 (n=44); HER-2 negative breast cancer, 2 (n=218); Bilateral breast cancer, 1 (n=33); General breast cancer,5 （n=2712） |
North america, 9 (n=1066); Europe, 5 (n=2603); Asia, 4（n=456） |
IHC, 11 (n=3339); WB, 7 (n=786) |
4125(1933/2192) | 229(34-1382) | 108(13-969) | 53 | 63 |
| Colorectal cancer | 7 | Colon cancer, 1 (n=125), Rectal cancer, 2 (n=121), Colorectal cancer, 4 (n=142) |
North america, 1 (n=35); Europe, 3 (n=210); Asia, 3（n=270） |
IHC, 4 (n=357); PCR, 3 (n=158) |
515(288/227) | 74(35-125) | 41(16-74) | 63 | 63 |
| Esophageal Cancer | 7 | None | Europe, 2 (n=238); Asia, 5（n=648） |
IHC, 7 (n=886) | 886(566/320) | 127(24-207) | 81(13-174) | 62 | 42 |
| Gastric cancer | 5 | None | South america, 1 (n=104); Asia,4（n=651） |
IHC, 5 (n=755) | 755(361/394) | 151(26-307) | 72(13-112) | 61 | 71 |
| Head and neck cancer | 7 | Nasopharyngeal cancer, 2 (n=270); Oral cancer, 2 (n=133), Tongue cancer, 1(n=47), General head and neck cancer, 2 (n=127) Clear cell renal cancer,2 (n=329); |
Europe, 2 (n=118); Asia,5（n=459） |
IHC, 6 (n=506); PCR, 1 (n=71) | 577(283/294) | 82(47-194) | 40(16-88) | 56 | 48 |
| Renal cancer | 6 | Advanced renal cancer, 1 (n=117); General renal cancer, 3 (n=318) |
Europe, 3 (n=325); Asia, 3（n=439） |
IHC, 4 (n=543); PCR, 2 (n=221) |
764(436/328) | 127(51-225) | 73(32-110) | 64 | 62 |
| Lung cancer | 7 | Advanced non-small cell lung cancer, 2 (n=100); Non-small cell lung cancer, 3 (n=394), Lung cancer, 2 (n=233) |
North america, 3 (n=254); Europe, 1 (n=61); Asia,3（n=412） |
IHC, 5 (n=632); PCR, 1 (n=79); FACS, 1 (n=16) |
727(295/432) | 103(16-208) | 42(5-117) | 64 | 46 |
| Melanoma | 4 | Uveal melanoma, 1 (n=25); Melanoma, 3 (n=143) |
Europe, 4 (n=168) | IHC, 4 (n=168) | 168(74/94) | 42(25-71) | 19(7-31) | 59 | 50 |
| Gynecologic cancer | 8 | Ovarian cancer, 6 (n=622); Vulvar cancer, 1 (n=30); Cervival cancer, 1 (n=174) |
Europe, 2 (n=360); Asia,6（n=466） |
IHC, 8 (n=826) | 826(549/277) | 103(30-241) | 69(19-214) | 56 | 66 |
| Pancreatic cancer | 2 | None | Europe, 2 (n=320) | IHC, 2 (n=320) | 320(254/66) | 160(71-249) | 127(39-215) | 63 | ND |
| Prostate cancer | 2 | None | Asia, 2 (n=109) | IHC, 2 (n=109) | 109(54/55) | 55(52-57) | 27(18-36) | 69 | 39 |
| Liver cancer | 2 | None | North america, 1 (n=75); Asia, 1（n=181） |
IHC, 2 (n=256) | 256(138/118) | 128(75-181) | 69(47-91) | 51 | 44 |
| Sarcoma | 2 | Soft tissue sarcoma, 1 (n=112); Osteosarcoma, 1 (n=56) |
Asia, 2 (n=168) | IHC, 1 (n=56); PCR, 1(n=112) | 168(97/71) | 84(56-112) | 49(39-58) | 18 | 38 |
| Gallbladder cancer | 1 | None | Asia, 1 (n=72) | IHC, 1 (n=72) | 72(50/22) | 72 | 50 | 60 | 30 |
| Total | 85 | North america, 18 (n=1796) Europe, 25 (n=4493); Asia, 41（n=4639） South america, 1 (n=104) | IHC, 65 (n=9101); PCR, 8 (n=641); WB, 7 (n=786); FACS, 5 (n=504) | 11032(5791/5241) | 130(16-1382) | 68(5-969) | 58 | 53 |